Developer docs
API playgroundTry for free, no card

Search company profiles

Kangstem Biotech

Full company profile

uuid000jd7r

Namestring
Kangstem Biotech
Legal namestring
강스템바이오텍 (주)
Websiteurl
kangstem.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Kangstem Biotech is a KOSDAQ-listed South Korean biotechnology company developing cell therapeutics based on allogeneic umbilical cord blood-derived mesenchymal stem cells (MSCs). Founded in 2010 and headquartered in Seoul, the company operates across five business lines: the Furestem stem-cell therapy franchise (Furestem-AD for atopic dermatitis, Furestem-OA for osteoarthritis, Furestem-RA for rheumatoid arthritis), the OSCA combination product pairing Furestem-OA with acellular cartilage matrix for knee osteoarthritis, organoid platforms (skin and islet organoids) for drug screening and regenerative medicine, CDMO services for cell-therapy developers via in-house GMP manufacturing, and the GD-11 cell-bio-derma cosmetic brand built on the proprietary USC1994 culture medium. The underlying technology is anchored in the SELAF™ one-stop platform covering cell separation, expansion, and clinical production.

The company's revenue model is diversified across product sales of stem-cell therapies and cosmetic SKUs, CDMO service contracts (notably with YJ Therapeutics for neural-progenitor cell therapy manufacturing that achieved IND approval), technology licensing and milestone payments from global pharma partnerships, and emerging organoid product sales. GTM is a hybrid of consumer e-commerce for GD-11 in Korea, enterprise field sales for CDMO and licensing deals, and event-driven partnership development at conferences such as BIO USA, where approximately 20 global pharmaceutical companies have been engaged for OSCA and organoid platform discussions.

Strategic positioning targets disease-modifying osteoarthritis drugs (DMOADs), an unmet category where no approved therapy modifies disease progression, with positive Phase 1 readouts (sustained through 24 months) and a 113-patient Phase 2a trial advancing toward topline in July 2026. The business is currently loss-making at scale (FY2025 net loss approximately KRW 96 billion against KRW 36 billion in revenue), consistent with a clinical-stage biotech in heavy R&D investment mode, offset by improving tax-loss carryforward ratios that have reduced KOSDAQ administrative risk from 52% in 2023 to 14% in 2025.

Short descriptiontext

Kangstem Biotech is a KOSDAQ-listed South Korean biotech developing allogeneic umbilical cord blood-derived mesenchymal stem cell therapies (Furestem line), organoid platforms, CDMO services, and a consumer health brand (GD-11), serving pharmaceutical companies and cell therapy developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, regenerative medicine, organoid technology, CDMO services, biopharmaceuticals
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy / Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales (Stem Cell Therapeutics)
TypeOne Time License
Description

Revenue from stem cell therapy products including Furestem-AD for atopic dermatitis and other pipeline products. The company reported approximately 36 billion KRW in sales revenue for 2025.

kangstem.com
2Technology Licensing and Milestone Payments
TypeLicensing Royalties
Description

Technology transfer contracts generating recurring milestone payments. In 2026, technology transfer contracts are expected to generate 2nd milestone payments, contributing additional revenue alongside existing sales.

kangstem.com
3CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services for cell therapy products. Kangstem provides manufacturing process development, GMP clinical trial material production, and regulatory support for clients like YJ Therapeutics.

kangstem.com
4Organoid Product Sales
TypeOne Time License
Description

Sales of organoid products for research and pharmaceutical applications. Expected to generate additional revenue in 2026.

kangstem.com
5Health & Beauty Products (GD-11)
TypeHardware Sales
Description

Cell bio-derma cosmetic brand based on international patented technology and USC1994 cell culture medium ingredients.

kangstem.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1CDMO and contract manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Contract-based pricing for GMP manufacturing, process development, and regulatory support services for cell therapy products.

kangstem.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Furestem
Description

Stem cell therapeutic product line including Furestem-OA Kit Inj. (osteoarthritis), Furestem-AD Inj. (atopic dermatitis), Furestem-RA Inj. (rheumatoid arthritis)

kangstem.com
+4 more records
Core offering1 text field

Kangstem Biotech develops and manufactures stem cell therapeutics targeting degenerative and inflammatory diseases such as osteoarthritis, atopic dermatitis, and rheumatoid arthritis, alongside organoid platforms for drug discovery and cosmetic applications. The company operates GMP manufacturing facilities, provides CDMO services for third-party cell therapy developers, and commercializes a dermo-cosmetic line (GD-11) based on its stem cell technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OSCA Phase 1: Significant pain and function improvement over time in medium and high dose groups, with complete recovery in some subjects. MRI analysis showed cartilage structure improvement signals.
+3 more records
Product overview1 text field

Kangstem Biotech is a global cell therapy pioneer developing stem cell-based treatments and organoid platforms. The portfolio centers on allogeneic umbilical cord blood-derived mesenchymal stem cell therapies including Furestem-AD (atopic dermatitis), Furestem-OA/OSCA (osteoarthritis), and Furestem-RA (rheumatoid arthritis), alongside an Organoid platform (skin and islet organoids) for drug screening and regenerative medicine. The company operates CDMO services leveraging GMP facilities, offers stem cell culture media products, and commercializes the GD-11 health and beauty cosmetic brand. The SELAF technology platform provides end-to-end stem cell development capabilities from isolation through clinical production.

Product and service8 records
1Furestem-OA
CategoryCell Therapy
Description

Stem cell therapy indicated for osteoarthritis, designed to regenerate cartilage and reduce inflammation in joints. Targeted at hospitals and orthopedic clinics treating patients with degenerative joint disease.

2Furestem-AD
CategoryCell Therapy
Description

Stem cell therapy indicated for atopic dermatitis, providing anti-inflammatory and immunomodulatory effects for chronic skin conditions. Targeted at dermatology clinics and hospitals.

3Furestem-RA
CategoryCell Therapy
Description

Stem cell therapy for rheumatoid arthritis, addressing autoimmune inflammation of joints. Targeted at hospitals and rheumatology specialists.

4OSCA
CategoryCell Therapy
Description

Allogeneic stem cell therapy product undergoing clinical trials, leveraging the company's cell therapy capabilities.

5Skin Organoids
CategoryOrganoid Platform
Description

Three-dimensional skin organoid platform derived from stem cell technology, used for drug discovery, toxicity testing, and cosmetic research applications. Targeted at research institutions and cosmetic companies.

6Islet Organoids
CategoryOrganoid Platform
Description

Islet organoid platform for diabetes research and drug development, leveraging stem cell-derived organoid technology. Targeted at pharmaceutical companies and research institutions.

7CDMO Services
CategoryManufacturing Services
Description

Contract Development and Manufacturing Organization services for cell therapy developers and biopharmaceutical companies, leveraging GMP-certified manufacturing capabilities and the SELAF™ platform. Targeted at biotech and pharma companies requiring cell therapy manufacturing capacity.

8GD-11 Dermo-Cosmetic Line
CategoryCosmetics
Description

Dermo-cosmetic product line developed from the company's stem cell technology and byproducts, marketed for skincare applications. Targeted at retail consumers seeking biotech-derived skincare.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Seoul National University (서울대학교)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Joint research collaboration for skin and hair follicle organoid manufacturing standardization. Seoul National University handles organoid source technology development and technology transfer, while Kangstem leads technology verification, standardization, and commercialization system establishment. This partnership is part of a 3-year government-supported project (2026-2028) focused on establishing manufacturing processes and quality control systems for organoid production.

kangstem.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-13
Description

CDMO partnership where Kangstem provides cell therapy manufacturing process development, GMP clinical trial material production, and regulatory submission support. YJ Therapeutics is developing cross-differentiated neural progenitor cell therapies for spinal cord injury, Parkinson's disease, and ALS. Kangstem supported their successful IND approval for 1/2a phase clinical trial.

3OSI (Organoid Standards Initiative) - Skin Division
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Active participation in OSI's skin division technical committee to establish skin organoid standardization guidelines. Results published in International Journal of Stem Cells (2024.05) demonstrating international standardization capabilities.

kangstem.com
4Primoristem Therapeutics (프리모리스테라퓨틱스)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exosome technology development specialist and related entity. Consolidation of this entity contributed to 2025 net loss reduction through equity valuation gains. The partnership brings exosome technology capabilities to Kangstem's platform.

kangstem.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Approximately 20 global pharmaceutical companies engaged for OSCA (osteoarthritis treatment) and skin/hair follicle organoid platform partnerships. Discussions cover joint development, technology licensing, and commercialization. One major global pharma company conducted on-site visits to Kangstem's research facilities and production facilities. Partnerships expected to advance through BIO USA 2026 discussions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean biotech commercializing Cartistem (umbilical cord blood-derived MSC therapy for cartilage regeneration). Closest direct peer to Kangstem in allogeneic MSC cartilage repair and Korean cell therapy commercialization.

TypeDirect peer
Description

Korean stem cell therapy company with approved autologous bone marrow MSC product Hearticellgram-AMI. Directly comparable as a Korean-listed stem cell therapeutics company with GMP manufacturing capability.

TypeDirect peer
Description

Korean biotech developing autologous stem cell therapy (Neuromast) for ALS. Comparable as a KOSDAQ-listed clinical-stage cell therapy company targeting rare/neuro indications.

TypeDirect peer
Description

Korean stem cell company with approved autologous MSC product (Cartistem predecessor) and broader regenerative medicine pipeline. Comparable in cell therapy focus and Korean market context.

TypeBroad incumbent
Description

Large Korean biopharma CDMO and biologics manufacturer. Comparable as a Korean-headquartered CDMO serving global biopharma, though operating at much larger scale and broader scope than Kangstem's cell therapy CDMO.

TypeBroad incumbent
Description

Global leader in cell and gene therapy CDMO services. Comparable as an established cell therapy CDMO peer that Kangstem's GMP services compete against for clinical-stage cell therapy clients.

TypeBroad incumbent
Description

Major global CDMO with cell therapy manufacturing capabilities. Comparable as a large, established CDMO serving cell therapy developers that competes for similar clinical-stage CDMO contracts.

TypeBroad incumbent
Description

Leading Korean biopharmaceutical company expanding into biosimilars and novel biologics. Comparable as a Korean-listed biopharma with broad therapeutic pipeline and global commercialization ambitions.

TypeEmerging player
Description

Clinical-stage US cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies. Comparable as a stem/cell therapy platform peer focused on allogeneic, off-the-shelf modalities.

TypeDirect peer
Description

Global leader in allogeneic MSC-based therapies (e.g., Remestemcel-L). Closest international comparable to Kangstem in allogeneic MSC pipeline scope and disease-modifying regenerative medicine positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kangstem Biotech

Cell Therapy / Biopharmaceuticalskangstem.com

Kangstem Biotech is a KOSDAQ-listed South Korean biotech developing allogeneic umbilical cord blood-derived mesenchymal stem cell therapies (Furestem line), organoid platforms, CDMO services, and a consumer health brand (GD-11), serving pharmaceutical companies and cell therapy developers.

What Kangstem Biotech does

Kangstem Biotech is a KOSDAQ-listed South Korean biotechnology company developing cell therapeutics based on allogeneic umbilical cord blood-derived mesenchymal stem cells (MSCs). Founded in 2010 and headquartered in Seoul, the company operates across five business lines: the Furestem stem-cell therapy franchise (Furestem-AD for atopic dermatitis, Furestem-OA for osteoarthritis, Furestem-RA for rheumatoid arthritis), the OSCA combination product pairing Furestem-OA with acellular cartilage matrix for knee osteoarthritis, organoid platforms (skin and islet organoids) for drug screening and regenerative medicine, CDMO services for cell-therapy developers via in-house GMP manufacturing, and the GD-11 cell-bio-derma cosmetic brand built on the proprietary USC1994 culture medium. The underlying technology is anchored in the SELAF™ one-stop platform covering cell separation, expansion, and clinical production.

The company's revenue model is diversified across product sales of stem-cell therapies and cosmetic SKUs, CDMO service contracts (notably with YJ Therapeutics for neural-progenitor cell therapy manufacturing that achieved IND approval), technology licensing and milestone payments from global pharma partnerships, and emerging organoid product sales. GTM is a hybrid of consumer e-commerce for GD-11 in Korea, enterprise field sales for CDMO and licensing deals, and event-driven partnership development at conferences such as BIO USA, where approximately 20 global pharmaceutical companies have been engaged for OSCA and organoid platform discussions.

Strategic positioning targets disease-modifying osteoarthritis drugs (DMOADs), an unmet category where no approved therapy modifies disease progression, with positive Phase 1 readouts (sustained through 24 months) and a 113-patient Phase 2a trial advancing toward topline in July 2026. The business is currently loss-making at scale (FY2025 net loss approximately KRW 96 billion against KRW 36 billion in revenue), consistent with a clinical-stage biotech in heavy R&D investment mode, offset by improving tax-loss carryforward ratios that have reduced KOSDAQ administrative risk from 52% in 2023 to 14% in 2025.

Kangstem Biotech firmographics

Firmographics
Name
Kangstem Biotech
Legal name
강스템바이오텍 (주)
Website
https://kangstem.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Kangstem Biotech is a KOSDAQ-listed South Korean biotech developing allogeneic umbilical cord blood-derived mesenchymal stem cell therapies (Furestem line), organoid platforms, CDMO services, and a consumer health brand (GD-11), serving pharmaceutical companies and cell therapy developers.
Ownership category
akta.pro rank

Kangstem Biotech industry classification

Industry
Product category
Cell Therapy / Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Stem cell therapy
  • Regenerative medicine
  • Organoid technology
  • CDMO services
  • Biopharmaceuticals

Where Kangstem Biotech is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Kangstem Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales (Stem Cell Therapeutics): Revenue from stem cell therapy products including Furestem-AD for atopic dermatitis and other pipeline products. The company reported approximately 36 billion KRW in sales revenue for 2025.
  2. Technology Licensing and Milestone Payments: Technology transfer contracts generating recurring milestone payments. In 2026, technology transfer contracts are expected to generate 2nd milestone payments, contributing additional revenue alongside existing sales.
  3. CDMO Services: Contract development and manufacturing services for cell therapy products. Kangstem provides manufacturing process development, GMP clinical trial material production, and regulatory support for clients like YJ Therapeutics.
  4. Organoid Product Sales: Sales of organoid products for research and pharmaceutical applications. Expected to generate additional revenue in 2026.
  5. Health & Beauty Products (GD-11): Cell bio-derma cosmetic brand based on international patented technology and USC1994 cell culture medium ingredients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCDMO and contract manufacturing services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Kangstem Biotech product offering

Product offering

Core offering

Kangstem Biotech develops and manufactures stem cell therapeutics targeting degenerative and inflammatory diseases such as osteoarthritis, atopic dermatitis, and rheumatoid arthritis, alongside organoid platforms for drug discovery and cosmetic applications. The company operates GMP manufacturing facilities, provides CDMO services for third-party cell therapy developers, and commercializes a dermo-cosmetic line (GD-11) based on its stem cell technology.

Product overview

Kangstem Biotech is a global cell therapy pioneer developing stem cell-based treatments and organoid platforms. The portfolio centers on allogeneic umbilical cord blood-derived mesenchymal stem cell therapies including Furestem-AD (atopic dermatitis), Furestem-OA/OSCA (osteoarthritis), and Furestem-RA (rheumatoid arthritis), alongside an Organoid platform (skin and islet organoids) for drug screening and regenerative medicine. The company operates CDMO services leveraging GMP facilities, offers stem cell culture media products, and commercializes the GD-11 health and beauty cosmetic brand. The SELAF technology platform provides end-to-end stem cell development capabilities from isolation through clinical production.

Differentiator

Problem solved

Functional benefit

Brands

  • Furestem: Stem cell therapeutic product line including Furestem-OA Kit Inj. (osteoarthritis), Furestem-AD Inj. (atopic dermatitis), Furestem-RA Inj. (rheumatoid arthritis)
  • SELAF
  • OSCA
  • GD-11
  • Organoid

Products and services

  • Furestem-OA Stem cell therapy indicated for osteoarthritis, designed to regenerate cartilage and reduce inflammation in joints. Targeted at hospitals and orthopedic clinics treating patients with degenerative joint disease.
  • Furestem-AD Stem cell therapy indicated for atopic dermatitis, providing anti-inflammatory and immunomodulatory effects for chronic skin conditions. Targeted at dermatology clinics and hospitals.
  • Furestem-RA Stem cell therapy for rheumatoid arthritis, addressing autoimmune inflammation of joints. Targeted at hospitals and rheumatology specialists.
  • OSCA Allogeneic stem cell therapy product undergoing clinical trials, leveraging the company's cell therapy capabilities.
  • Skin Organoids Three-dimensional skin organoid platform derived from stem cell technology, used for drug discovery, toxicity testing, and cosmetic research applications. Targeted at research institutions and cosmetic companies.
  • Islet Organoids Islet organoid platform for diabetes research and drug development, leveraging stem cell-derived organoid technology. Targeted at pharmaceutical companies and research institutions.
  • CDMO Services Contract Development and Manufacturing Organization services for cell therapy developers and biopharmaceutical companies, leveraging GMP-certified manufacturing capabilities and the SELAF™ platform. Targeted at biotech and pharma companies requiring cell therapy manufacturing capacity.
  • GD-11 Dermo-Cosmetic Line Dermo-cosmetic product line developed from the company's stem cell technology and byproducts, marketed for skincare applications. Targeted at retail consumers seeking biotech-derived skincare.

Quantifiable outcome

  • OSCA Phase 1: Significant pain and function improvement over time in medium and high dose groups, with complete recovery in some subjects. MRI analysis showed cartilage structure improvement signals.
  • +3 more outcomes

Companies that use Kangstem Biotech

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Kangstem Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kangstem Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Seoul National University (서울대학교)coreStrategic or Co-development Partner · 30 April 2026Joint research collaboration for skin and hair follicle organoid manufacturing standardization. Seoul National University handles organoid source technology development and technology transfer, while Kangstem leads technology verification, standardization, and commercialization system establishment. This partnership is part of a 3-year government-supported project (2026-2028) focused on establishing manufacturing processes and quality control systems for organoid production.
  • YJ Therapeutics (와이제이세라퓨틱스)coreStrategic or Co-development Partner · 13 February 2026CDMO partnership where Kangstem provides cell therapy manufacturing process development, GMP clinical trial material production, and regulatory submission support. YJ Therapeutics is developing cross-differentiated neural progenitor cell therapies for spinal cord injury, Parkinson's disease, and ALS. Kangstem supported their successful IND approval for 1/2a phase clinical trial.
  • OSI (Organoid Standards Initiative) - Skin DivisionminorStrategic or Co-development PartnerActive participation in OSI's skin division technical committee to establish skin organoid standardization guidelines. Results published in International Journal of Stem Cells (2024.05) demonstrating international standardization capabilities.
  • Primoristem Therapeutics (프리모리스테라퓨틱스)coreStrategic or Co-development PartnerExosome technology development specialist and related entity. Consolidation of this entity contributed to 2025 net loss reduction through equity valuation gains. The partnership brings exosome technology capabilities to Kangstem's platform.
  • Multiple Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerApproximately 20 global pharmaceutical companies engaged for OSCA (osteoarthritis treatment) and skin/hair follicle organoid platform partnerships. Discussions cover joint development, technology licensing, and commercialization. One major global pharma company conducted on-site visits to Kangstem's research facilities and production facilities. Partnerships expected to advance through BIO USA 2026 discussions.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Kangstem Biotech competitors and assessment

Company assessment

Direct peers

  • Medipost: Korean biotech commercializing Cartistem (umbilical cord blood-derived MSC therapy for cartilage regeneration). Closest direct peer to Kangstem in allogeneic MSC cartilage repair and Korean cell therapy commercialization.
  • Pharmicell: Korean stem cell therapy company with approved autologous bone marrow MSC product Hearticellgram-AMI. Directly comparable as a Korean-listed stem cell therapeutics company with GMP manufacturing capability.
  • Corestem: Korean biotech developing autologous stem cell therapy (Neuromast) for ALS. Comparable as a KOSDAQ-listed clinical-stage cell therapy company targeting rare/neuro indications.
  • NatureCell: Korean stem cell company with approved autologous MSC product (Cartistem predecessor) and broader regenerative medicine pipeline. Comparable in cell therapy focus and Korean market context.
  • Mesoblast: Global leader in allogeneic MSC-based therapies (e.g., Remestemcel-L). Closest international comparable to Kangstem in allogeneic MSC pipeline scope and disease-modifying regenerative medicine positioning.

Broad incumbents

  • Samsung Biologics: Large Korean biopharma CDMO and biologics manufacturer. Comparable as a Korean-headquartered CDMO serving global biopharma, though operating at much larger scale and broader scope than Kangstem's cell therapy CDMO.
  • Lonza Group: Global leader in cell and gene therapy CDMO services. Comparable as an established cell therapy CDMO peer that Kangstem's GMP services compete against for clinical-stage cell therapy clients.
  • Catalent: Major global CDMO with cell therapy manufacturing capabilities. Comparable as a large, established CDMO serving cell therapy developers that competes for similar clinical-stage CDMO contracts.
  • Celltrion: Leading Korean biopharmaceutical company expanding into biosimilars and novel biologics. Comparable as a Korean-listed biopharma with broad therapeutic pipeline and global commercialization ambitions.

Emerging players

  • Fate Therapeutics: Clinical-stage US cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies. Comparable as a stem/cell therapy platform peer focused on allogeneic, off-the-shelf modalities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Kangstem Biotech social profiles

Digital presence

Kangstem Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kangstem Biotech leadership team

Management profile

Number of profiles

Profiles4 records

Kangstem Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Kangstem Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kangstem Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kangstem Biotech

What does Kangstem Biotech do?

Kangstem Biotech develops and manufactures stem cell therapeutics targeting degenerative and inflammatory diseases such as osteoarthritis, atopic dermatitis, and rheumatoid arthritis, alongside organoid platforms for drug discovery and cosmetic applications. The company operates GMP manufacturing facilities, provides CDMO services for third-party cell therapy developers, and commercializes a dermo-cosmetic line (GD-11) based on its stem cell technology.

Is Kangstem Biotech a public or private company?

Kangstem Biotech is a public company. It is classified as public and is currently operating.

When was Kangstem Biotech founded?

Kangstem Biotech was founded in 2010. It employs 11 to 50 people.

Where is Kangstem Biotech based?

Kangstem Biotech is headquartered in Seoul, South Korea, in the Asia region.

How does Kangstem Biotech make money?

Five revenue lines are on record. Product Sales (Stem Cell Therapeutics) is the primary driver. The others are technology Licensing and Milestone Payments, CDMO Services, organoid Product Sales and health & Beauty Products (GD-11).

Who are Kangstem Biotech's main competitors?

Direct peers on record are Medipost, Pharmicell, Corestem, NatureCell and Mesoblast. Broad incumbents are Samsung Biologics, Lonza Group, Catalent and Celltrion. Fate Therapeutics is listed as an emerging player.

Does Kangstem Biotech have an API?

No public API is recorded for Kangstem Biotech.

What industry is Kangstem Biotech in?

Kangstem Biotech's product category is Cell Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver2026's Game-Changer: How OSCA from Gangstem Biotech is Revolutionizing Osteoarthritis CareKangstem Biotech's OSCA, a stem cell and cartilage matrix injection, showed pain relief and joint function improvement in a Phase 2a trial of 113 patients with moderate knee osteoarthritis. MRI scores on the MOCART scale improved, suggesting potential structural repair. The company plans to accelerate development of therapies that improve joint structure beyond symptom relief.NaverOSCA vs. Placebo: How Stem Cell Treatment for Knee Pain is Changing LivesKangstem Biotech received the final report for its Phase 2a trial of OSCA, a stem cell treatment for knee osteoarthritis, involving 113 patients. The treatment showed statistically significant pain relief and functional improvement versus placebo at 24 weeks, with MRI suggesting joint structure benefits. The company plans long-term follow-ups and FDA pre-consultations next year.NaverRevolutionary Skin Organoids: How Vascularized Models Are Transforming Atopic Dermatitis ResearchKang Stem Biotech published findings on a vascularized skin organoid platform in Experimental & Molecular Medicine, which induced atopic dermatitis-like inflammation and responded to upadacitinib and dupilumab. The model replicates skin barrier weakening and immune responses, offering a testing ground for drug candidates before clinical trials.Nate[Pharmaceuticals+] Samsung Biologics, 2.7 trillion won polypeptide acquisition process, etc.: Nate NewsKangstem Biotech signed a joint evaluation research contract with a global pharmaceutical company using an organoid platform for skin immune diseases. The contract is in the stage of evaluating the efficacy and mechanism of action of the partner's new drug candidates. Kangstem is expanding its organoid collaboration with another global pharma following a July MTEA.Yonhap News AgencyKangstem Biotech to raise 50 bln won via stock saleKangstem Biotech announced a stock sale to raise 50 billion won (US$43.4 million) on Monday. The company will issue about 12.37 million common shares at 4,040 won per share to existing shareholders, with proceeds primarily for operations.PR NewswireSoutheast Asia Atopic Dermatitis Therapeutics Markets to 2024 - How will Novel IL-4Ra Inhibitor Therapy Dupixent, which Holds First-to-Market Advantage, Contribute to GrowthResearch and Markets announced a market research report projecting the Southeast Asia Atopic Dermatitis therapeutics market will grow from $423.2 million in 2017 to $848.6 million by 2024, at a compound annual growth rate of 10.5%. The report highlights Dupixent (dupilumab) as a first-in-class IL-4Ra inhibitor and the first biologic approved for AD, with expected launches in Singapore and Taiwan positioned as significant near-term market events. The analysis covers market forecasts across eight Southeast Asian countries and examines pipeline therapies including tralokinumab, furestem-AD, baricitinib, PAC-14028, and PF-04965842.PR Newswire APACORIG3N(TM) and Kangstem Biotech Announce Collaboration to Study Neural Stem CellsORIG3N and Kangstem Biotech announced a collaboration to study induced neural stem cells (iNSCs) for disease modeling. Kangstem will provide iNSCs to ORIG3N, which will use its disease-modeling platform. The collaboration aims to advance Kangstem's iNSCs in disease modeling applications.PR NewswireORIG3N™ and Kangstem Biotech Announce Collaboration to Study Neural Stem CellsORIG3N, Inc. and Kangstem Biotech announced a scientific collaboration to study induced neural stem cells (iNSCs) for disease modeling applications. Under the agreement, Kangstem Biotech will provide its patient-specific iNSCs to ORIG3N, which will leverage its in-house disease-modeling platform to advance the use of these cells in neurological disorder research and drug screening. Both companies characterize the partnership as a step toward advancing personalized regenerative medicine.